SCHEMBL29567119

SCHEMBL29567119

CN1CCN(c2cccc(Oc3cc(Cl)nc(NS(=O)(=O)c4cnn(C)c4)n3)c2Cl)CC1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HTR6 P50406 15/20 0.42
▸ DRD3 P35462 4/20 0.39
▸ DRD2 P14416 4/20 0.39
▸ HTR1A P08908 4/20 0.39
▸ HTR2A P28223 3/20 0.39
▸ HTR2C P28335 2/20 0.39
▸ DRD4 P21917 1/20 0.39
▸ HTR7 P34969 3/20 0.37
▸ KMT2A Q03164 2/20 0.37
▸ CYP1A2 P05177 1/20 0.37
▸ CYP3A4 P08684 1/20 0.37
▸ CYP2D6 P10635 1/20 0.37
▸ HTR1D P28221 1/20 0.37
▸ HTR1B P28222 1/20 0.37
▸ HTR1E P28566 1/20 0.37
▸ HTR1F P30939 1/20 0.37
▸ CYP2C19 P33261 1/20 0.37
▸ ADRA1B P35368 1/20 0.37
▸ HTR2B P41595 1/20 0.37
▸ HTR4 Q13639 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26809792 0.89 HTR6 (0.37) HTR6DRD3DRD2HTR1AHTR2A
SCHEMBL29567125 0.89 HTR6 (0.37) HTR6DRD3DRD2HTR1AHTR2A
SCHEMBL24309255 0.88 DRD2 (0.36) HTR6DRD2HTR1AHTR2ADRD4
SCHEMBL29566539 0.88 DRD2 (0.36) HTR6DRD2HTR1AHTR2ADRD4
SCHEMBL29567213 0.86 DRD2 (0.41) HTR6DRD2HTR1AHTR2AHTR2C
SCHEMBL26807398 0.85 HTR6 (0.35) HTR6DRD3DRD2HTR1AHTR2A
SCHEMBL24309483 0.84 HTR1A (0.41) HTR6DRD3DRD2HTR1AHTR2A
SCHEMBL29566556 0.84 HTR1A (0.41) HTR6DRD3DRD2HTR1AHTR2A
SCHEMBL29566863 0.84 HTR1A (0.37) HTR6DRD2HTR1AHTR2ADRD4
SCHEMBL26807391 0.84 HTR1A (0.37) HTR6DRD2HTR1AHTR2ADRD4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4225748-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR Vertex Pharmaceuticals Incorporated (US) 2023-08-16 — — EP disclosed
WO-2022076627-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR VERTEX PHARMACEUTICALS INCORPORATED (US) 2022-04-14 — — WO disclosed
Send feedback